Company Overview and News

4
QIAGEN Launches QIAstat-Dx Panel in Europe, Widens Suite

4h zacks
QIAGEN N.V. (QGEN - Free Report) recently announced the European launch of its next-generation multiplex gastrointestinal panel — QIAstat-Dx panel. This completely integrated molecular analysis of gastrointestinal (GI) syndromes analyzes and detects the 24 most common viral, bacterial and parasitic pathogens which can cause GI infections.
PFZ AZN BLT BHP AZN BHPBF BBL BHP BHPLF 500680 PFE PFIZER

1
UPDATE 1-Australian watchdog's appeal against Pfizer ruling dismissed by court

15h reuters
(Reuters) - Australia’s competition watchdog said on Friday the High Court dismissed its special leave application to appeal a court’s decision on whether Pfizer Inc’s local unit used its market power to limit competition for its cholesterol-lowering drug Lipitor.
PFZ 500680 PFE PFIZER

1
Court dismisses Australian watchdog's appeal against Pfizer ruling

16h channelnewsasia
Australia's competition watchdog said on Friday the High Court dismissed its special leave application to appeal a court's decision on whether Pfizer Inc's local unit used its market power to limit competition for its cholesterol-lowering drug Lipitor.
PFZ 500680 PFE PFIZER

1
Court dismisses Australian watchdog's appeal against Pfizer ruling

16h reuters
(Reuters) - Australia’s competition watchdog said on Friday the High Court dismissed its special leave application to appeal a court’s decision on whether Pfizer Inc’s local unit used its market power to limit competition for its cholesterol-lowering drug Lipitor.
PFZ 500680 PFE PFIZER

1
Pfizer to cut around 2pc of jobs through early next year

2018-10-18 malaymail
NEW YORK, Oct 18 — US drugmaker Pfizer Inc plans to reduce its global headcount by around 2 per cent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities.
PFZ DTK 500680 PFE PFIZER

1
Pfizer to cut around 2% of jobs through early next year

2018-10-18 bworldonline
NEW YORK — US drugmaker Pfizer Inc plans to reduce its global head count by around 2 percent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities.
PFZ DTK 500680 PFE PFIZER

1
Merck, Pfizer combo treatment meets main goals of kidney cancer trial

2018-10-18 channelnewsasia
Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer.
PFZ 500680 PFE PFIZER

1
Pfizer to cut around 2 per cent of jobs through early next year

2018-10-17 financialexpress
U.S. drugmaker Pfizer Inc plans to reduce its global headcount by around 2 percent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities. Pfizer has around 90,000 employees worldwide. Pfizer spokeswoman Sally Beatty said the job cuts were “about creating a simpler, more efficient structure and not achieving cost savings.
PFZ DTK 500680 PFE PFIZER

1
Pfizer to cut around 2 percent of jobs through early next year

2018-10-17 channelnewsasia
U.S. drugmaker Pfizer Inc plans to reduce its global headcount by around 2 percent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities.
PFZ DTK 500680 PFE PFIZER

1
Pfizer to cut around 2 percent of jobs through early next year

2018-10-17 reuters
NEW YORK (Reuters) - U.S. drugmaker Pfizer Inc (PFE.N) plans to reduce its global headcount by around 2 percent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities.
PFZ DTK 500680 PFE PFIZER

1
Pfizer to cut around 2 pct of jobs through early next year

2018-10-17 reuters
NEW YORK, Oct 17 (Reuters) - U.S. drugmaker Pfizer Inc plans to reduce its global headcount by around 2 percent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities.
PFZ DTK 500680 PFE PFIZER

1
UPDATE 1-FDA approves Pfizer's drug for advanced breast cancer

2018-10-16 reuters
(Reuters) - The U.S. Food and Drug Administration said on Tuesday it approved Pfizer Inc’s drug for an advanced form of breast cancer tied to an inherited gene mutation.
PFZ MYGN 500680 PFE PFIZER

1
FDA approves Pfizer's breast cancer drug

2018-10-16 channelnewsasia
The U.S. Food and Drug Administration said on Tuesday it approved Pfizer Inc's drug for advanced form of breast cancer.
PFZ MYGN 500680 PFE PFIZER

10
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

2018-10-16 zacks - 1
Looking for broad exposure to the Large Cap Blend segment of the US equity market? You should consider the First Trust Capital Strength ETF (FTCS - Free Report) , a passively managed exchange traded fund launched on 07/06/2006.
IVV PFZ PGR CTRL CI IVV 500680 PFE PFIZER

10
UPDATE 1-U.S. to propose TV ads for drugs must include list prices

2018-10-15 reuters
(Reuters) - The U.S. government, in an effort to increase pressure on drugmakers to lower costs for U.S. consumers, said on Monday it will propose requiring companies to include the price of their prescription medicines in television ads.
PFZ ABBV 500680 PFE PFIZER ABBV

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...